Unresectable Hepatocellular Carcinoma Market Report 2026

The unresectable hepatocellular carcinoma market size has grown strongly in recent years. It will grow from $2.01 billion in 2025 to $2.21 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing incidence of chronic liver disease, rising prevalence of cirrhosis-related cancer, expansion of oncology treatment centers, availability of systemic therapy options, improvements in diagnostic capabilities.

The unresectable hepatocellular carcinoma market size is expected to see strong growth in the next few years. It will grow to $3.22 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to increasing development of next-generation immunotherapies, rising focus on biomarker-driven treatment selection, expansion of precision oncology programs, growing investment in liver cancer research, increasing adoption of minimally invasive therapies. Major trends in the forecast period include increasing adoption of immunotherapy-based treatments, rising use of molecularly targeted therapies, growing focus on combination treatment approaches, expansion of personalized oncology care, enhanced use of advanced diagnostic imaging.

The rising prevalence of liver cancer is expected to drive the growth of the unresectable hepatocellular carcinoma market going forward. Liver cancer occurs when healthy liver cells are overtaken by rapidly dividing tumor cells, resulting in malignant growth that disrupts normal liver function. The increasing prevalence of liver cancer is driven by metabolic disorders, viral hepatitis infections, alcohol-related liver disease, and obesity-related liver complications. The unresectable hepatocellular carcinoma market addresses this need by providing therapeutic options such as systemic therapies, immunotherapies, radiofrequency ablation, and liver-directed procedures for patients who are not candidates for surgical tumor removal. For example, in May 2025, according to the Cancer Council Victoria, an Australia-based not-for-profit organization, 667 individuals were diagnosed with liver cancer in Victoria in 2023, including 469 males (70.3%) and 198 females (29.7%). Current diagnosis rates stand at 11.8 per 100,000 males and 4.4 per 100,000 females. Therefore, the rising prevalence of liver cancer is propelling the growth of the unresectable hepatocellular carcinoma market.

Increasing healthcare expenditure is expected to further support the growth of the unresectable hepatocellular carcinoma market. Health expenditure refers to the total funds spent on activities that promote, restore, and maintain health. Healthcare spending is rising due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often involve higher costs, increasing overall healthcare expenditure. This expenditure is particularly important in unresectable hepatocellular carcinoma, as treatment options become more complex and costly as the disease progresses. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency overseeing Medicare and Medicaid, U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or approximately $14,570 per individual. Therefore, rising healthcare expenditure is driving the growth of the unresectable hepatocellular carcinoma market.

Leading companies in the unresectable hepatocellular carcinoma market are focusing on innovative treatments, such as combination therapies, to improve outcomes for patients with unresectable liver cancer. Combination therapies involve using two or more treatments simultaneously to enhance efficacy, target multiple disease pathways, or reduce resistance. For example, in March 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, launched Opdivo (nivolumab) Intravenous Infusion in combination with Yervoy. Opdivo is a human anti-PD-1 monoclonal antibody that works by blocking the interaction between PD-1 on T cells and its ligands (PD-L1 and PD-L2) on cancer cells. Normally, this interaction suppresses T cells’ ability to attack cancer cells, but by blocking it, Opdivo helps T cells recognize and eliminate cancer cells more effectively.

Major companies operating in the unresectable hepatocellular carcinoma market are Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Innovent Biologics Inc., Sirtex Medical Limited, Genentech Inc., CStone Pharmaceuticals, Delcath Systems Inc., Celsion Corporation.

North America was the largest region in the unresectable hepatocellular carcinoma market in 2025. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the unresectable hepatocellular carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the unresectable hepatocellular carcinoma market by increasing costs of imported oncology drugs, biologics, diagnostic imaging equipment, and treatment delivery systems used in cancer management. Hospitals and cancer centers in North America and Europe are most affected due to dependence on imported advanced therapies, while Asia-Pacific faces pricing pressures on biologic drug manufacturing. These tariffs are increasing treatment costs and affecting patient access. However, they are also supporting local pharmaceutical production, regional clinical research expansion, and domestic development of oncology therapeutics.

The unresectable hepatocellular carcinoma market research report is one of a series of new reports that provides unresectable hepatocellular carcinoma market statistics, including unresectable hepatocellular carcinoma industry global market size, regional shares, competitors with a unresectable hepatocellular carcinoma market share, detailed unresectable hepatocellular carcinoma market segments, market trends and opportunities, and any further data you may need to thrive in the unresectable hepatocellular carcinoma industry. This unresectable hepatocellular carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Unresectable hepatocellular carcinoma is an aggressive tumor that often develops in the context of cirrhosis and chronic liver disease. Treatments for unresectable hepatocellular carcinoma include surgical resection, liver transplantation, ablation, and embolization.

The main types of unresectable hepatocellular carcinoma are primary, secondary, and benign liver growths. Primary indicates the main or most significant form, with hepatocellular carcinoma being the most common type of primary liver cancer. Treatment options include chemotherapy, molecularly targeted therapy, immunotherapy, and others, which are administered in hospitals, specialty clinics, and cancer centers.

The unresectable hepatocellular carcinoma market includes revenues earned by entities by providing first-line agents, surgical resection, and liver transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.